| Specialty Retail Industry | Consumer Discretionary Sector | Terry Agrivos CEO | OTC GREY Exchange | 29102A103 CUSIP |
| GH Country | - Employees | - Last Dividend | 24 Nov 2009 Last Split | - IPO Date |
Emerging World Pharma, Inc. is an investment entity focused on the pharmaceutical sector within developing nations. Established in 1997 and headquartered in Sunyani, Ghana, the company has evolved from its original incarnation as Tubearoo, Inc. until it adopted its current identity in November 2009. Its core mission is to drive advancements in healthcare by investing in generic pharmaceutical manufacturers in burgeoning markets. Emerging World Pharma, Inc. facilitates these companies' growth by providing essential resources such as production infrastructure, the recruitment and training of local workforce, and the necessary raw materials. The company strategically positions its investments toward pharmaceutical firms that have existing agreements with church and other nongovernmental organizations, the government, and wholesalers, aiming to create a sustainable impact on local health systems through accessible and affordable medication.
Emerging World Pharma, Inc. offers holistic support to its partner companies in setting up state-of-the-art manufacturing facilities. This includes assistance in the architectural design, construction, and outfitting of production plants with the latest pharmaceutical manufacturing technologies.
Understanding the importance of skilled labor in the pharmaceutical industry, the company invests in the local workforce. This involves not just hiring individuals but also providing comprehensive training programs to ensure that employees are well-versed in current pharmaceutical manufacturing practices and quality control standards.
To guarantee the uninterrupted production of pharmaceuticals, Emerging World Pharma, Inc. ensures a steady supply of high-quality raw materials. This support helps in mitigating the risks associated with supply chain disruptions and aids in maintaining consistent product availability in the market.